Gut Incretin Release as a Mediator of Metabolic Effects of Metformin in Type 2 Diabetic Patients with Chronic Heart Failure

Diabetes ◽  
2018 ◽  
Vol 67 (Supplement 1) ◽  
pp. 465-P
Author(s):  
EVA STOLARIKOVA ◽  
JAN KOPECKY ◽  
JIRI VELEBA ◽  
KATERINA VELEBOVA ◽  
LENKA BELINOVA ◽  
...  
Keyword(s):  
Heart Failure ◽  
Chronic Heart Failure ◽  
Metabolic Effects ◽  
Diabetic Patients ◽  
Type 2 Diabetic Patients ◽  
Type 2 Diabetic

scholarly journals Clinical Prole of Chronic Heart Failure in Hospitalized Type 2 Diabetic Patients

2018 ◽  
Vol 6 (1-2) ◽  
pp. 67-70
Author(s):  
Shahana Parveen ◽  
AMB Safdar ◽  
Faria Afsana ◽  
AKM Mohibullah ◽  
Ramendra Nath Sarker
Keyword(s):  
Heart Failure ◽  
Chronic Heart Failure ◽  
Regional Wall Motion ◽  
Diabetic Patients ◽  
Type 2 Diabetic Patients ◽  
Regional Wall Motion Abnormalities ◽  
Wall Motion Abnormalities ◽  
The Mean ◽  
Type 2 Diabetic

Objective: To see the clinical profile of chronic heart failure in hospitalized type 2 diabetic subjects. Method: This cross-sectional study was carried out on a total of 100 type 2 diabetic patients with chronic heart failure, in the Department of Cardiology, BIRDEM, over a period of six months between July to December 2012. Results: The mean age of the study subjects was 60.9 ± 11.7 years with male to female ratio being roughly 2:1. The mean duration of diabetes mellitus was 9.15 years. Among the study subjects 72% were on insulin and 18% on oral hypoglycemic agents; 10% were on combined insulin and oral hypoglycemic agent. Dyspnea and cough were invariably present. About 88% subjects had edema, 39% raised JVP, and 13% murmur. Bilateral basal crepitation was found in 56% cases. While mean fasting blood glucose (FBG), postprandial blood glucose (PPBG) level and HbA1C were 10 mmol/l, 16.7 mmol/l and 9.9% respectively, mean serum creatinine was 2.07 mg/dl. Among study subjects, raised ESR (48%), elevated WBC count (50%) and raised BNP level (64.6%) were seen. Chest X- ray revealed cardiomagaly (70%), reticulonodular shadow in both lung fields (11%) and septal thickening (15%). ECG findings of the patients were old infarct (72%), IHD (66%), RV hypertrophy (40%) and arrhythmia (17%). Most common echocardiographic findings of the subjects were regional wall motion abnormalities (78%), Mild LV systolic dysfunction (64%) with Grade-I diastolic dysfunction being 70% and moderate to severe pulmonary arterial hypertension being 40%. Conclusion: Raised BNP level, presence of old infarct in ECG and regional wall motion abnormalities in echocardiography are the common clinical findings among patients with chronic heart failure. Ibrahim Card Med J 2016; 6 (1&2): 67-70

Metabolic effects of liraglutide in type 2 diabetic patients.

2018 ◽  
Author(s):  
Mariola Mendez Muros ◽  
Cristobal Morales Portillo ◽  
Antonio Manuel Garrido Hermosilla ◽  
Vianney Magaly Santiago Septimo ◽  
Antonio Perez Perez ◽  
...  
Keyword(s):  
Metabolic Effects ◽  
Diabetic Patients ◽  
Type 2 Diabetic Patients ◽  
Type 2 Diabetic

scholarly journals Sodium-Glucose Cotransporter-2 Inhibitor (SGLT2i) as a Primary Preventative Agent in the Healthy Individual: A Need of a Future Randomised Clinical Trial?

2021 ◽  
Vol 8 ◽  
Author(s):  
Dan Xu ◽  
Owain Chandler ◽  
Cleo Wee ◽  
Chau Ho ◽  
Jacquita S. Affandi ◽  
...  
Keyword(s):  
Heart Failure ◽  
Type 2 Diabetes ◽  
Clinical Trial ◽  
Diabetic Patients ◽  
Atherosclerotic Cardiovascular Disease ◽  
Healthy Individuals ◽  
Type 2 Diabetic Patients ◽  
Sodium Glucose Cotransporter ◽  
Type 2 Diabetic

Sodium-glucose cotransporter-2 inhibitors (SGLT2i) are a relatively novel class of drug for treating type 2 diabetes mellitus (T2DM) that inhibits glucose reabsorption in the renal proximal tubule to promote glycosuria and reduce blood glucose levels. SGLT2i has been clinically indicated for treating T2DM, with numerous recent publications focussing on both primary and secondary prevention of cardiovascular and renal events in Type 2 diabetic patients. The most recent clinical trials showed that SGLT2i have moderately significant beneficial effects on atherosclerotic major adverse cardiovascular events (MACE) in patients with histories of atherosclerotic cardiovascular disease. In this review and analysis, SGLT2i have however demonstrated clinically significant benefits in reducing hospitalisation for heart failure and worsening of chronic kidney disease (CKD) irrespective of pre-existing atherosclerotic cardiovascular disease or previous heart failure history. A meta-analysis suggests that all SGLT2 inhibitors demonstrated the therapeutic benefit on all-cause and cardiovascular mortality, as shown in EMPAREG OUTCOME study with a significant decrease in myocardial infarction, without increased stroke risk. All the above clinical trial recruited type 2 diabetic patients. This article aims to postulate and review the possible primary prevention role of SGLT2i in healthy individuals by reviewing the current literature and provide a prospective overview. The emphasis will include primary prevention of Type 2 Diabetes, Heart Failure, CKD, Hypertension, Obesity and Dyslipidaemia in healthy individuals, whom are defined as healthy, low or intermediate risks patients.

scholarly journals Safety and Efficacy of Adding Dapagliflozin to Furosemide in Type 2 Diabetic Patients With Decompensated Heart Failure and Reduced Ejection Fraction

2020 ◽  
Vol 7 ◽  
Author(s):  
Ayman Ibrahim ◽  
Ramadan Ghaleb ◽  
Hossam Mansour ◽  
Amr Hanafy ◽  
Naggeh M. Mahmoud ◽  
...  
Keyword(s):  
Heart Failure ◽  
Ejection Fraction ◽  
Serum Potassium ◽  
Decompensated Heart Failure ◽  
Diabetic Patients ◽  
Type 2 Diabetic Patients ◽  
Significant Difference ◽  
Kidney Functions ◽  
Type 2 Diabetic

Background: Heart failure is the most common cause of hospitalization in elderly patients. It is likely that many of the mechanisms that contribute to reductions in systolic and diastolic function, seen in diabetic patients, place them at an increased risk of heart failure. Diuretic therapy, especially loop diuretics, is the usual way of managing congestion, particularly in volume-overloaded patients. Little is known about the beneficial effect of dapagliflozin when added to loop diuretics in managing patients with decompensated heart failure.Aim: To assess the effect of the addition of dapagliflozin to furosemide in managing decompensated patient with heart failure and reduced left ventricular ejection fraction in terms of weight loss and dyspnea improvement.Patients and Methods: The study included 100 type 2 diabetic patients who were admitted with decompensated heart failure. The study population was randomly divided into two arms. Serum electrolytes and kidney functions were followed up during their hospital stay.Results: With dapagliflozin, there was a statistically significant difference between the two groups regarding the change in body weight and body mass index. The diuresis parameters including urine output, total fluid loss, and fluid balance also showed a statistically significant difference in favor of the use of dapagliflozin, with no significant change in serum potassium or kidney functions. There was significant improvement in patient-reported dyspnea scores with the use of dapagliflozin.Conclusions: Dapagliflozin may provide a new drug option in the treatment of heart failure especially among vulnerable group of diabetics. It had no remarkable effects on serum potassium level and kidney functions.Clinical Trial Registration:www.ClinicalTrials.gov, identifier: NCT04385589.

Sign in / Sign up

Export Citation Format

Share Document